Skip to main content
. 2016 Mar 29;114(7):809–812. doi: 10.1038/bjc.2016.45

Table 4. Progression-free and overall survival in MPC and LAPC cohorts.

  Overall survival
Progression-free survival
  Median OS 6 mo 12 mo 18 mo Median PFS 6 mo 12 mo 18 mo
Metastatic (37 pts) 10.2 mo 81% 38% 22% 6.1 mo 54% 14% 9%
LAPC (29 pts) 26.6 mo 100% 86% 62% 17.8 mo 97% 69% 62%

Abbreviations: mo, months; Pts, patients.